
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2334586/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis. Gut, 2022, 71, 593-604.	6.1	62
2	Asymptomatic saccular portal vein aneurysm: a case report and review of the literature. Journal of Ultrasound, 2022, , 1.	0.7	3
3	Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease. Frontiers in Aging Neuroscience, 2022, 14, .	1.7	4
4	Outcome of liver cancer patients with SARSâ€CoVâ€⊋ infection: An International, Multicentre, Cohort Study. Liver International, 2022, 42, 1891-1901.	1.9	11
5	Management of intermediateâ€stage hepatocellular carcinoma in the elderly with transcatheter arterial chemoembolization failure: Retreatment or switching to systemic therapy?. International Journal of Clinical Practice, 2021, 75, e13733.	0.8	2
6	Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease. Internal and Emergency Medicine, 2021, 16, 1239-1245.	1.0	7
7	A Novel Nutraceuticals Mixture Improves Liver Steatosis by Preventing Oxidative Stress and Mitochondrial Dysfunction in a NAFLD Model. Nutrients, 2021, 13, 652.	1.7	16
8	Direct antiviral agents improve systemic redox balance in patients affected by chronic hepatitis C. Free Radical Biology and Medicine, 2021, 165, 24.	1.3	0
9	Temporal profile of SARS-CoV-2 viral load in posterior nasopharyngeal samples: Analysis of 944 patients in Apulia, Italy. International Journal of Infectious Diseases, 2021, 104, 696-700.	1.5	1
10	Inhibition of nuclear factor (erythroid-derived 2)-like 2 promotes hepatic progenitor cell activation and differentiation. Npj Regenerative Medicine, 2021, 6, 28.	2.5	14
11	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, 2021, 3, 100260.	2.6	36
12	Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Scientific Reports, 2021, 11, 13944.	1.6	16
13	Pharmacological and Toxicological Effects of Phytocannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health. Pharmaceuticals, 2021, 14, 965.	1.7	17
14	Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression. International Journal of Molecular Sciences, 2021, 22, 436.	1.8	40
15	Genetic Polymorphisms and Clinical Features in Diabetic Patients With Fatty Liver: Results From a Single-Center Experience in Southern Italy. Frontiers in Medicine, 2021, 8, 737759.	1.2	3
16	Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. American Journal of Translational Research (discontinued), 2021, 13, 2379-2387.	0.0	5
17	Liver fibrosis by FibroScan [®] independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. Liver International, 2020, 40, 347-354.	1.9	59
18	The Dual Role of Glutamatergic Neurotransmission in Alzheimer's Disease: From Pathophysiology to Pharmacotherapy. International Journal of Molecular Sciences, 2020, 21, 7452.	1.8	63

#	Article	IF	CITATIONS
19	The Glucose Metabolic Pathway as A Potential Target for Therapeutics: Crucial Role of Glycosylation in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 7739.	1.8	12
20	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107684.	1.2	11
21	Direct-acting antivirals restore systemic redox homeostasis in chronic HCV patients. Free Radical Biology and Medicine, 2020, 156, 200-206.	1.3	5
22	NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients. Journal of Hepatology, 2020, 73, S165.	1.8	0
23	Tocilizumab and liver injury in patients with COVID-19. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095918.	1.4	33
24	Two-Dimensional Shear Wave Elastography versus Transient Elastography: A Non-Invasive Comparison for the Assessment of Liver Fibrosis in Patients with Chronic Hepatitis C. Diagnostics, 2020, 10, 313.	1.3	9
25	Molecular Aspects and Treatment of Iron Deficiency in the Elderly. International Journal of Molecular Sciences, 2020, 21, 3821.	1.8	14
26	Lipid Metabolism in Development and Progression of Hepatocellular Carcinoma. Cancers, 2020, 12, 1419.	1.7	91
27	From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases. Frontiers in Pharmacology, 2020, 11, 124.	1.6	83
28	NAFLD fibrosis score identifies not only advanced liver fibrosis but also chronic vascular complications in type 2 diabetic patients. Digestive and Liver Disease, 2020, 52, e45.	0.4	0
29	Chronic psychosocial defeat differently affects lipid metabolism in liver and white adipose tissue and induces hepatic oxidative stress in mice fed a highâ€fat diet. FASEB Journal, 2019, 33, 1428-1439.	0.2	8
30	Diagnostic reliability of the procalcitonin serum marker in septic frail patient. Aging Clinical and Experimental Research, 2019, 31, 727-732.	1.4	9
31	Directâ€acting antivirals for HCV treatment in older patients: A systematic review and metaâ€analysis. Journal of Viral Hepatitis, 2019, 26, 1249-1256.	1.0	17
32	Pharmacological Treatment of Depression in Alzheimer's Disease: A Challenging Task. Frontiers in Pharmacology, 2019, 10, 1067.	1.6	37
33	THU-323-Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. Journal of Hepatology, 2019, 70, e302.	1.8	Ο
34	The effect of direct-acting antivirals on hepatocellular carcinoma recurrence: still waiting for the turning point. Hepatobiliary Surgery and Nutrition, 2019, 8, 525-526.	0.7	1
35	SAT-314-Liver fibrosis by FibroScan is highly prevalent in type 2 diabetic patients with NAFLD and fairly normal liver enzymes but increased uric acid. Journal of Hepatology, 2019, 70, e777-e778.	1.8	1
36	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA Cardiology, 2019, 4, 526.	3.0	26

#	Article	IF	CITATIONS
37	Risk of Statin-Induced Hypertransaminasemia. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 131-140.	1.2	5
38	Impact of genetic polymorphisms associated with NAFLD on hepatic and vascular complications in diabetes. Digestive and Liver Disease, 2019, 51, e28-e29.	0.4	0
39	Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis. Hepatology Communications, 2019, 3, 504-512.	2.0	53
40	Stroke prevention in patients from Latin American countries with nonâ€valvular atrial fibrillation: Insights from the GARFIELDâ€AF registry. Clinical Cardiology, 2019, 42, 553-560.	0.7	16
41	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	1.2	45
42	Management and 1‥ear Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	1.6	44
43	Molecular Mechanisms Involved in HCC Recurrence after Direct-Acting Antiviral Therapy. International Journal of Molecular Sciences, 2019, 20, 49.	1.8	35
44	Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Acta Cardiologica, 2019, 74, 309-318.	0.3	16
45	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	1.0	28
46	Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. American Journal of Gastroenterology, 2018, 113, 368-375.	0.2	82
47	Synergistic interaction of fatty acids and oxysterols impairs mitochondrial function and limits liver adaptation during nafld progression. Redox Biology, 2018, 15, 86-96.	3.9	54
48	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.2	16
49	Why are outcomes different for registry patients enrolled prospectively and retrospectively? Insights from the global anticoagulant registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 27-35.	1.8	15
50	Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues. Antioxidants, 2018, 7, 93.	2.2	71
51	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	1.1	80
52	Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. Free Radical Biology and Medicine, 2017, 111, 173-185.	1.3	101
53	Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. Free Radical Biology and Medicine, 2017, 111, 281-293.	1.3	58
54	Biopsychosocial predictors of interferon-related depression in patients with Hepatitis C. Asian Journal of Psychiatry, 2017, 26, 24-28.	0.9	8

#	Article	IF	CITATIONS
55	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017, 103, 307-314.	1.2	205
56	Impact of gender on event rates at 1â€year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	0.8	30
57	In-hospital mortality and length of stay in cirrhotic patients with sepsis treated with non-selective beta-blockers. Digestive and Liver Disease, 2017, 49, e15.	0.4	1
58	Alterations of Clock Gene RNA Expression in Brain Regions of a Triple Transgenic Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 615-631.	1.2	57
59	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	1.2	161
60	DAAs increase serum VEGF level: a rationale for tumour risk recurrence during anti-HCV treatment. Journal of Hepatology, 2017, 66, S735.	1.8	1
61	Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: A metaâ€analysis of randomized trials. United European Gastroenterology Journal, 2017, 5, 511-518.	1.6	67
62	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	0.8	92
63	Evolving quality standards for large-scale registries: the GARFIELD-AF experience. European Heart Journal Quality of Care & Clinical Outcomes, 2016, 3, qcw058.	1.8	27
64	Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry. Internal and Emergency Medicine, 2016, 11, 1059-1066.	1.0	90
65	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. International Journal of Cardiology, 2016, 223, 543-547.	0.8	71
66	Effects of dietary fatty acids and cholesterol excess on liver injury: A lipidomic approach. Redox Biology, 2016, 9, 296-305.	3.9	42
67	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	1.2	13
68	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal, 2016, 37, 2882-2889.	1.0	222
69	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	1.1	118
70	DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment. PLoS ONE, 2016, 11, e0167934.	1.1	96
71	Mitochondrial Signaling and Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Implications. Current Pharmaceutical Design, 2016, 22, 2689-2696.	0.9	18
72	Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins. Medicine (United States), 2015, 94, e1409.	0.4	0

#	Article	IF	CITATIONS
73	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S12-20.	0.9	74
74	Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir. Clinical Management Issues, 2015, 9, 57-62.	0.3	1
75	Oxysterols and redox signaling in the pathogenesis of non-alcoholic fatty liver disease. Free Radical Research, 2013, 47, 881-893.	1.5	26
76	780 LIVER TOXICITY INDUCED BY AMIODARONE IS DEPENDENT ON MITOCHONDRIA COMPLEX I IMPAIRMENT, OXPHOS UNCOUPLING AND CARDIOLIPIN PEROXIDATION. Journal of Hepatology, 2010, 52, S303.	1.8	0
77	High prevalence of false positive SARS-CoV2 serology in a cohort of patients with liver autoimmune diseases. Exploration of Medicine, 0, , 372-377.	1.5	1